Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05924139 · ClinicalTrials.gov registry record · NA
Omega-3 Fatty Acid Supplementation to Enhance Performance
A NA study of Body Composition and Muscle Soreness, sponsored by Baylor University.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT05924139: Completed NA study of Body Composition and Muscle Soreness, sponsored by Baylor University.
NCT05924139 is a NA study of Body Composition and Muscle Soreness that has completed, run by Baylor University. The registered enrollment target is 33 participants, below the 115-participant average among 20 other Body Composition trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05924139, a NA study of Body Composition and Muscle Soreness, has completed, sponsored by Baylor University.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this intervention study is to determine if omega-3 fatty acid supplementation as compared to placebo improves performance in track and field athletes. The main questions it aims to answer are: 1. Can performance be improved 2. Can strength be enhanced 3. Will positive body composition changes occur (lean vs fat mass) 4. Will feelings of muscle soreness be diminished Participants will take either omega-3 fatty acid supplements or placebo and continue with their sport specific training regimen. Researchers will compare the supplement group to placebo group to determine if there are any significant differences.
Primary Outcome
lower body strength will be evaluated via a counter movement jump
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Omega-3 fatty acid
Study Locations (1)
Texas
- Baylor University - Waco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-03-06 |
| Est. Completion | 2023-06-02 |
| Phase | NA |
What the finished NCT05924139 record still lists
NCT05924139 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 115-participant average among 20 other Body Composition trials with a reported enrollment target (71% lower).
The record links to 3 conditions, with Body Composition appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05924139 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05924139 about?
NCT05924139 is a clinical study titled "Omega-3 Fatty Acid Supplementation to Enhance Performance". The goal of this intervention study is to determine if omega-3 fatty acid supplementation as compared to placebo improves performance in track and field athletes. The main questions it aims to answer are: 1. Can performance be improved 2. Can strength be enhanced 3. Will positive body composition c...
What is the current status of trial NCT05924139?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2023-03-06. Estimated completion is 2023-06-02.
What conditions does trial NCT05924139 study?
This clinical trial studies the following conditions: Body Composition, Muscle Soreness, Strength.
What interventions are being tested in trial NCT05924139?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Omega-3 fatty acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05924139?
This trial is sponsored by Baylor University, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05924139 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Body Composition
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05924139's enrollment target sits among peer trials
33 18th of 20 higher than 3 of 20 other Body Composition trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Body Composition trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
How Does Continued Use of Green Light Therapy Impact Outcomes?
RECRUITING · NA
-
ENRICH Nurse-Family Partnership Study
RECRUITING · NA
-
Feasibility and Potential Efficacy of Herbs and Spices for Improving Dietary Quality in College Students: A Pilot Study
RECRUITING · NA
-
Can EmeraldLED Reshape Your Body With Continued Use?
RECRUITING · NA
-
Role of Body Composition in Large for Gestational Age Infants (LGA) With Oral Feeding Difficulty
RECRUITING · NA
-
Discover Better Body Composition With Green Light!
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI